Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

S. W. Yee; Y. Momozawa; Y. Kamatani; R. F. Tyndale; R. M. Weinshilboum; M. J. Ratain; K. M. Giacomini; M. Kubo

doi:10.1002/cpt.405

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

S. W. Yee, Y. Momozawa, Y. Kamatani, R. F. Tyndale, R. M. Weinshilboum, M. J. Ratain, K. M. Giacomini, M. Kubo

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

Original language	English
Pages (from-to)	423-426
Number of pages	4
Journal	Clinical Pharmacology and Therapeutics
DOIs	https://doi.org/10.1002/cpt.405
Publication status	Published - 01-11-2016
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cpt.405

Cite this

@article{376bcf456d5041b2a8d6be97063f9365,

title = "Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration",

abstract = "Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.",

author = "Yee, {S. W.} and Y. Momozawa and Y. Kamatani and Tyndale, {R. F.} and Weinshilboum, {R. M.} and Ratain, {M. J.} and Giacomini, {K. M.} and M. Kubo",

note = "Publisher Copyright: {\textcopyright} 2016 The American Society for Clinical Pharmacology and Therapeutics",

year = "2016",

month = nov,

day = "1",

doi = "10.1002/cpt.405",

language = "English",

pages = "423--426",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Genomewide Association Studies in Pharmacogenomics

T2 - Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

AU - Yee, S. W.

AU - Momozawa, Y.

AU - Kamatani, Y.

AU - Tyndale, R. F.

AU - Weinshilboum, R. M.

AU - Ratain, M. J.

AU - Giacomini, K. M.

AU - Kubo, M.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

AB - Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=84990196642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990196642&partnerID=8YFLogxK

U2 - 10.1002/cpt.405

DO - 10.1002/cpt.405

M3 - Article

C2 - 27256705

AN - SCOPUS:84990196642

SN - 0009-9236

SP - 423

EP - 426

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

ER -

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this